Bull or Bear, Seeking Alpha is there

Markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings.

Bull or Bear, Seeking Alpha is there

Markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings.

Analysis

All Analysis
AI Tech
Basic Materials
Biotech
Bonds
Closed End Funds
Commodities
Communication Services
Consumer
Consumer Staples
Cryptocurrency
Dividend Ideas
Dividend Quick Picks
Dividend Strategy
Dividends
Editors' Picks
Electric Vehicles
Energy
ETF Analysis
ETFs and Funds
Financial Advisor
Financials
Fixed Income
Forex
Gold & Precious Metals
Growth
Healthcare
Industrial
Interest Rates
Investing Strategy
IPOs
Long Ideas
Magnificent 7
Market Outlook
Micro-Caps
Mutual Funds
Podcast
Portfolio Strategy
Quick Picks & Lists
Real Estate
REITs
Retirement
Small-Caps
Stock Ideas
Tech
Trending Analysis
U.S. Economy
Undercovered Stocks
Utilities
Value
Weight Loss

Latest Healthcare & Biotech Stock Analysis

ICON: A High Probability Of Success In The Uncertain R&D Process

ICLRStanislas CapitalYesterday, 4:44 PM1 Comment

Genmab A/S: Circling Back On This Complicated Story

GMABBret JensenYesterday, 3:10 PM

Butterfly Network: Not Quite Ready To Soar Yet

BFLYMacrotips TradingYesterday, 2:45 PM1 Comment

ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success

IBRXEdmund InghamYesterday, 2:40 PM3 Comments

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

CGONTerry ChrisomalisYesterday, 2:09 PM1 Comment

Novo Nordisk's CagriSema May Trump Lilly's Zepbound - Buy This Dip

NVOJuxtaposed IdeasYesterday, 2:00 PM2 Comments

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

VIRBiotech BeastYesterday, 12:57 PM

Protalix BioTherapeutics' Phase 1 Data Bolsters Gout Aspirations (Rating Upgrade)

PLXStephen AyersYesterday, 11:25 AM5 Comments

Thermo Fisher: The Cycle Has Already Turned Around

TMOSergio MelladoYesterday, 4:22 AM

Butterfly Network: Time For A Pause

BFLYBret JensenThu, Dec. 124 Comments

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

ACRVGalzus ResearchThu, Dec. 12

Cellectis: Poised To Start Answering Questions In 2025

CLLSGalzus ResearchThu, Dec. 122 Comments

ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL

ADCTTerry ChrisomalisThu, Dec. 12

Lantheus Holdings: A Growing Business With Dominant Market Share

LNTHJames LongThu, Dec. 122 Comments

Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff

KROSEdmund InghamThu, Dec. 124 Comments

Kyverna Therapeutics: CAR T-Cells Trying To Impact Inflammatory Disorders

KYTXGalzus ResearchThu, Dec. 12

Omeros Corporation: Investment Opportunity Finely Poised As The Market Waits For Key Updates

OMEREdmund InghamThu, Dec. 123 Comments

Spyre Therapeutics: Different Name, Same Tune

SYREBret JensenThu, Dec. 12

IQVIA Holdings: Share Price Disconnected From Growth Outlook

IQVBiologicsThu, Dec. 121 Comment

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

RXRXBioCGT InvestorThu, Dec. 124 Comments

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

CRDFGalzus ResearchThu, Dec. 1218 Comments

Hims & Hers: Look At What Matters Most

HIMSOakoff InvestmentsThu, Dec. 124 Comments

InMode: Product Origination And Undervaluation Make The Stock A Buy

INMDKingfisher ResearchThu, Dec. 12

IQVIA: Will This Beaten-Down Stock Bounce Back? 3 Things To Know

IQVHF AnalystThu, Dec. 121 Comment

Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable

PHATAvisol Capital PartnersWed, Dec. 118 Comments

Teleflex Incorporated: Compelling Only On One Metric

TFXBret JensenWed, Dec. 11

ImmunityBio's Cash Burn And Dilution Dampen Anktiva's Potential

IBRXStephen AyersWed, Dec. 114 Comments

Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns

PFEThe Value PortfolioWed, Dec. 1134 Comments

CVS: Why I'm Selling My Worst Holding Of 2024

CVSSungarden Investment PublishingWed, Dec. 1162 Comments

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

RVPHTejo Strategy InvestingWed, Dec. 111 Comment

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

CMRXGalzus ResearchWed, Dec. 117 Comments

GSK Is Doing The Right Things But Can't Catch A Break - Rating Downgrade

GSK, GLAXFEdmund InghamWed, Dec. 119 Comments

OraSure Technologies: Discounted Assets With An Attractive Free Call Option

OSURAmericanStockPickersWed, Dec. 112 Comments

NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts

NAMSTerry ChrisomalisWed, Dec. 116 Comments

Betting Big On AbbVie: A Prescription For Growth And Dividends

ABBV, ABBV:CALeo NelissenWed, Dec. 1135 Comments

Immunome: A Recently Acquired Lead Asset And A Small Market

IMNMAvisol Capital PartnersWed, Dec. 11

12 3 4 5 Next

Investing Groups

Portfolios

Find & Compare

Subscriptions

Analysis

Latest Healthcare & Biotech Stock Analysis